Drug Profile
Imidazolyl ethanamide pentandioic acid - Valenta Pharmaceuticals
Alternative Names: Ingavirin; Myelo 001; VitaglutamLatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Valenta Pharmaceuticals
- Developer Myelo Therapeutics; Valenta Pharmaceuticals
- Class Antivirals; Imidazoles; Small molecules
- Mechanism of Action Apoptosis inhibitors; Granulocyte stimulants; Haematopoiesis stimulants; Neutrophil stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neutropenia; Viral infections
- Phase III COVID 2019 infections; Influenza virus infections; Respiratory tract infections
- No development reported Acute radiation syndrome; Myelosuppression
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in Germany (PO)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Myelosuppression in Germany (PO)
- 15 Jul 2022 Phase-III clinical trials in Influenza virus infections (Adjunctive treatment, In infants) in Russia (PO) (NCT05269290)